Document:

Exhibit 10.5

 

INTELLECTUAL
PROPERTY ASSIGNMENT AGREEMENT

                This
INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT (this “Agreement”) is made and entered into as of July 24,
2017 (the “Effective Date”), by and between Paul M. DiPerna, having an address at 17995 Bear Valley
Lane, Escondido CA 92027 (the “Assignor”), Quasuras, Inc., a Delaware corporation (“Assignee”)
and Modular Medical, Inc. (“Modular”).

R
E C I T A L S

                WHEREAS,
Assignor is the owner of the Assigned IP (as defined below);

                WHEREAS,
Assignee wishes to acquire all right, interest and title in the Assigned IP pursuant to and in accordance with the terms and conditions
set forth therein;

                WHEREAS,
as a condition to Modular taking the following actions on or prior to the Effective Date, Modular shall, among other items, (i)
acquire (the “Acquisition”) Assignee by issuing to Assignor (and the other shareholders of Assignee)
shares of common stock in Modular in exchange for all such persons’ shares of the Assignee (which equals 100% of the issued
and outstanding share of the Assignee), and (ii) agree to sell and certain investors agree to buy shares of common stock of Modular,
certain of the net proceeds which will be used in the business of Assignee;

                WHEREAS,
as a result of the Acquisition, Assignee will become a wholly-owned subsidiary of Modular;

                NOW
THEREFORE, in consideration of the above recitals and of the mutual promises and conditions in this Agreement, and other valuable
consideration, receipt of which is hereby acknowledged, it is agreed as follows:

A
G R E E M E N T

                1.             Definitions.
As used in this Agreement, the following terms shall have the meanings set forth in this Section 1.

                                (a)               “Assigned
IP” (a) the patents and patent applications listed on Schedule A hereto, and any future patents that claim
priority from or the benefit of the filing date of any of the patents listed on Schedule A, and including any and all continuations,
divisions, reissues, extensions, supplementary protection certificates and the like with respect to any of the foregoing (the
“Patents”); (b) issued, pending and abandoned U.S. and foreign trademarks and trademark applications
set forth on Schedule B hereto (the “Trademarks”); and (c) all rights of any kind whatsoever
of Assignor accruing under any of the foregoing provided by applicable law of any jurisdiction, by international treaties and
conventions and otherwise throughout the world.

                                (b)               “Intellectual
Property” means all intellectual and technological property of whatever kind including but not limited to all source
code, object code, text, graphics, photos, database technology, ecommerce technology, server technology, operating systems, algorithms,
development tools relating to the Assigned IP.

    	1

    	 

    

                                (c)               “Intellectual
Property Rights” means copyrights (including rights in software), patents, patent applications, trademarks, trademark
applications, trade names, service marks, business names (including internet domain names), design rights, database rights, rights
in undisclosed or confidential information (such as know-how, proprietary ideas, trade secrets, techniques, methods, specifications,
inventions (whether patentable or not) and the like) and all other intellectual property or similar proprietary rights of whatever
nature (whether registered or not and including applications to register or rights to apply for registration) in and to the Intellectual
Property which may now or in the future subsist anywhere in the world.

                2.             Transfer
and Assignment. For good and valuable consideration including, but not limited to, the Acquisition and the Capital Raise,
the receipt and sufficiency of which are hereby acknowledged, Assignor hereby assigns, sells and transfers to Assignee all of
Assignor’s right, title and interest in and to the Assigned IP, the Intellectual Property and the Intellectual Property
Rights, together with all goodwill related thereto and all rights to fully exploit, and to enforce all infringement claims in
respect of any of, such Intellectual Property (the “Assignment”).

                3.             Ownership
of Intellectual Property. Assignor represents and warrants to the Assignee and Modular that Assignor is the developer
and sole and exclusive owner of the Assigned IP, the Intellectual Property and Intellectual Property Rights, no person has rights
with respect thereto including, but not limited to, receive any proceeds herefrom or therefrom whether in a sale, license and/or
otherwise, has the full exclusive rights and power to enter into and perform this Agreement and to effect the Assignment and that
the execution and performance of this Agreement by such does not and will not violate or interfere with any agreement, understanding
or contract to which Assignor and/or any of his Affiliates is a party to and/or is effected by, does not violate any rights of
any other Person; does not violate any law, rule and/or regulation that no part of the Assigned IP, the Intellectual Property
or Intellectual Property Rights or the exercise of the rights granted hereunder violates or infringes upon any rights of any Person,
including, but not limited to, any such Person’s copyrights, trademark rights, patent rights, trade secrets rights, or contractual,
common law or statutory rights and no Person has any rights to, including the proceeds from any sale, and/or Lien (as defined
below) on any of the Assigned IP, the Intellectual Property and/or the Intellectual Property Rights. The term “Lien” means
any lien, security interest, mortgage, deed of trust, charge, claim, encumbrance, pledge, option, right of first offer or first
refusal and any other right or interest of others of any kind or nature, actual or contingent, or other similar encumbrance of
any nature whatsoever.; and the term “Person” means an individual, a corporation, a partnership, an
association, a trust or other entity or organization, including a government or political subdivision or an agency or instrumentality
thereof.

    	2

    	 

    

                4.             Governing
Law; Venue. This Agreement shall be governed by and construed solely and exclusively under and pursuant to the laws of
the State of New York as applied to releases among New York residents entered into and to be performed entirely within New York.
Each of the Parties expressly and irrevocably (i) agrees that any legal suit, action or proceeding arising out of or relating
to this Agreement will be instituted exclusively in either the New York State Supreme Court, County of New York, or in the United
States District Court for the Southern District of New York; (ii) waives any objection they may have now or hereafter to the venue
of any such suit, action or proceeding; and (iii) consents to the in personam jurisdiction of either the New York State Supreme
Court, County of New York, or the United States District Court for the Southern District of New York in any such suit, action
or proceeding. Each of the Parties hereto further agrees to accept and acknowledge service of any and all process which may be
served in any such suit, action or proceeding in either the New York State Supreme Court, County of New York, or in the United
States District Court for the Southern District of New York and agrees that service of process upon it mailed by certified mail
to its address will be deemed in every respect effective service of process upon it, in any such suit, action or proceeding.

                5.             Execution
and Counterparts. This Agreement and any amendments, waivers, consents, or supplements may be executed in one or more
counterparts, each of which when so executed and delivered shall be deemed an original, but all of which counterparts together
shall constitute but one and the same instrument. This Agreement shall become effective upon the execution of a counterpart hereof
by each of the parties hereto. Delivery of an executed counterpart of a signature page to this Agreement, any amendments, waivers,
consents or supplements, by facsimile or email shall be as effective as delivery of a manually executed counterpart thereof.

                6.             Severability.
If any portion of this Agreement is held and/or found to be invalid, superseded and/or unenforceable, in whole or in part, the
remainder of this Agreement shall nevertheless remain in full force and effect and the invalid and unenforceable portions hereof
shall be deemed modified to the extent necessary to render that portion valid and enforceable to the maximum extent permitted
by law.

                7.             Entire
Agreement. This Agreement contains the entire understanding and agreement between the Parties with respect to the
matters contained herein, and replaces and supersedes any prior understandings or agreements between any and all of them, with
respect to the subject matter hereof.

                8.             Successors
and Assigns. This Assignment shall be binding upon and shall inure to the benefit of the parties hereto and their
respective successors and assigns.

                9.             Third
Party Beneficiary. The parties hereto expressly acknowledge and agree that Modular is a third-party beneficiary to
this Agreement and is entitled to the rights, remedies and benefits hereunder and may enforce the provisions hereof as if
it were a party hereto. Except as set forth in the preceding sentence, this Agreement shall not confer any rights, benefits or
remedies to any Person not a party hereto.

[Remainder of
page intentionally left blank]

    	3

    	 

    

[SIGNATURE
PAGE OF IP ASSIGNMENT AGREEMENT]

                IN
WITNESS WHEREOF, the parties hereto have hereby executed and delivered this Agreement as of the date first written above.

	 	 	                                                   
	 	ASSIGNOR
	 	 	 
	 	 	 
	 	Paul DiPerna
	 	 	 
	 	ASSIGNEE
	 	 	 
	 	QUASURAS, INC.
	 	 	 
	 	By: 	 
	 	Name: Paul DiPerna
	 	Title: Chief Executive Officer
	 	 	 
	 	MODULAR MEDICAL, INC.
	 	 	 
	 	By:	 
	 	Name: Morgan C. Frank
	 	Title: Chief Executive Officer

[END OF SIGNATURE
PAGE OF IP ASSIGNMENT AGREEMENT]

    	4

    	 

    

SCHEDULE
A

Patents
and Patent Applications

U.S. Provisional Patent Application
No. 61/947,032, filed March 3, 2014, naming Paul DiPerna as inventor, and titled “Fluid Delivery Damping and Delivery Pump”

                 

International Patent Application
No. PCT/US2015/018525, filed March 3, 2015, naming Paul DiPerna as inventor, and titled “Fluid Delivery Pump”

                 

U.S. Non-provisional Patent
Application No. 15/122,132, filed August 26, 2016, naming Paul DiPerna as inventor, and titled “Fluid Delivery Pump”

                 

U.S. Provisional Patent Application
No. 62/529,086, filed July 6, 2017, naming Paul DiPerna as inventor, and titled “Variable Flow Orifice with Dynamic Control
Feedback.”

    	5

    	 

    

SCHEDULE
B

Trademarks
and Trademark Applications

None.

    	6Exhibit 10.6

 

TECHNOLOGY
ROYALTY AGREEMENT

 

This
Technology Royalty Agreement (hereinafter referred to as the “Agreement”), is entered into as of the 24th
day of July, 2017 by and among Paul M. DiPerna, an individual (“DiPerna”) and Quasuras, Inc., a Delaware corporation
(the “Company”) and Modular Medical, Inc., a Nevada corporation and owner of all of the issued and outstanding capital
stock of the Company (“Modular”). DiPerna, Modular and the Company are sometimes collectively referred to as the “Parties”,
and individually as a “Party”.

 

RECITALS:

 

WHEREAS,
DiPerna, the Company and Modular have entered into an Intellectual Property Assignment Agreement dated as of July 24, 2017 (the
“IP Assignment Agreement”) pursuant to which DiPerna is assigning and transferring to the Company all of DiPerna’s
right, title and interest in and to certain intellectual property and related items.

 

NOW,
THEREFORE, in consideration for the promises set forth herein and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally
bound, do hereby agree as follows:

 

AGREEMENT

 

1. Definitions.

 

1.1
The capitalized terms “Assigned IP”, “Intellectual Property” and “Intellectual Property Rights”
as used herein shall have the meaning set forth in the IP Assignment Agreement.

 

1.2
“Royalty Product” shall mean (i) any product or device which is covered in whole or claimed in any of the Assigned
IP; (ii) any product or device incorporating, utilizing or made by any process which utilizes the Assigned IP, the Intellectual
Property, or the Intellectual Property Rights and (iii) any other insulin or diabetes related product or device sold, licensed
or otherwise commercialized by the Company, Modular or any of their respective subsidiaries during the term of this Agreement.
For the avoidance of doubt, “Royalty Product” shall not include any devices or products of any entity that acquires
the Company or Modular that are in existence on the date of such acquisition;

 

2.
Royalties. In consideration for the assignment by DiPerna to the Company of the Assigned IP, the Intellectual Property
and the Intellectual Property Rights pursuant to the IP Assignment Agreement, Company shall pay DiPerna royalties as follows:

 

2.1 Royalty
Rate.  Subject to the Royalty Cap set forth in Section 2.2, the Company shall pay DiPerna a royalty on sales
of any Royalty Product sold by the Company and/or Modular and each of their respective, subsidiaries and/or affiliate companies
anywhere in the world equal to: (i) US $0.75 on each Sale of a Royalty Product, or (ii) five percent (5%) of the Gross Sales Price
of a Royalty Product, whichever is less. For purposes of this Agreement, a “Sale” of a Royalty Product shall be deemed
to have been made when the Royalty Product is delivered to a customer and the Company and/or its parents, subsidiaries and/or
affiliate companies receives payment and such funds clear and become immediately available funds from the customer. “Gross
Sales Price” means the gross amount of money received by the Company and/or its parents, subsidiaries and/or affiliate companies
in connection with the Sale of a Royalty Product to customers, minus sales, use, V.A.T. and other taxes, shipping, insurance
and related costs and expenses paid by the Company, its parents, subsidiaries relating to such Royalty Product. Royalty Product
sold by a sublicensee pursuant to a sublicense agreement are subject to the royalties due DiPerna hereunder.

    	1

    	 

    

2.2 Royalty
Cap. Payment of the royalties set forth in Section 2.1 shall cease, and this Agreement shall terminate, at such time as
the total sum of royalty payments actually paid to DiPerna pursuant to this Agreement equals Ten Million Dollars (US $10,000,000);
provided, however, that the Company shall have the option to terminate this Agreement at any time upon the payment to DiPerna
of the difference between (i) the total royalty payments actually paid to DiPerna to date and (ii) $10,000,000.

 

2.3
Best Efforts.  The Company shall use its commercially reasonable best efforts to promote and market the
sale of Royalty Product and to maximize royalty payments to DiPerna pursuant to this Section 2.  “Best efforts” means,
with respect to a given goal, the efforts consistent with the practice of comparable technology companies with respect to similar
products of comparable market potential that a reasonable person in the position of the Company would use so as to achieve that
goal as expeditiously as possible.

 

2.4
Effective Date. This Agreement shall have no force and effect until such time that the Company and/or Modular sells
or licenses its first Royalty Product, at which time this Agreement shall become effective. For the avoidance of doubt, DiPerna
shall be paid the royalty payment due hereunder on the first sale or license of a Royalty Product.

 

3.
Payments, Reporting and Records.

3.1
Payment of the royalties specified in Section 2.1, if any such royalty is due, for the preceding calendar quarter shall be
made by the Company to DiPerna within forty-five (45) days after March 31, June 30, September 30 and December 31
of each year during the term of this Agreement. After termination or expiration of this Agreement, a final payment shall be made
by the Company covering the last whole or partial calendar quarter. Each quarterly payment shall be accompanied by a written statement
of royalties due, as described in Section 3.4 hereunder.      

3.2
All monetary payments due hereunder are expressed in and shall be paid by check or wire transfer payable in United States dollars,
without deduction of exchange, collection or other charges, to DiPerna.     

3.3
The Company shall keep and preserve, in accordance with U.S. Generally Accepted Accounting Principles (GAAP), consistently applied,
complete and accurate books, records and accounts containing particulars that are necessary for the purpose of showing the amounts
payable to DiPerna hereunder. Said books, records and accounts shall be kept at the Company’s principal place of business
or the principal place of business of the appropriate division of the Company to which this Agreement relates. No more than once
per annum said books and supporting data shall be open, upon reasonable notice at all reasonable times and places during business
hours for two (2) years following the end of the calendar year to which they pertain, to the inspection of an independent
auditor engaged at DiPerna’s cost mutually agreeable to the parties for the purpose of verifying the Company’s royalty
statement or compliance in other respects with this Agreement.

    	2

    	 

    

3.4
The Company shall, within forty five (45) days after March 31, June 30, September 30 and December 31, of each year,
deliver to DiPerna true and accurate reports, giving such particulars of the business conducted by the Company and its sublicensees
during the preceding calendar quarter under this Agreement as shall be pertinent to a royalty accounting hereunder. These reports
shall be duly signed by an authorized signatory of the Company on behalf of the Company and shall include at least the following:
(a) true and accurate information regarding sales of Royalty Product sufficient to determine and verify the royalties due
and owing, if any, pursuant to Section 2.1; (b) total royalties due, if any; and (c) names and addresses of all sublicensees
of the Company.      

3.5
With each such report submitted, the Company shall pay to DiPerna the royalties due and payable under this Agreement. If no royalties
are due, the Company shall so report.

4.
[Reserved]

 

5.
[Reserved].   

 

6.
Assignment. During the term of this Agreement, neither Party shall assign
any benefit or burden under this Agreement without prior written consent of the other Party, which shall not be unreasonably withheld,
delayed or conditioned, except that (i) the Company may assign its rights and
obligations under this Agreement to Modular or any company or person with which it may merge or consolidate or to any company
or person to whom it may transfer substantially all of its assets or to any company or person which may acquire such Party (including,
in each case, any company created as a new vehicle upon any such merger, transfer or acquisition), and (ii) DiPerna may freely
assign his royalty payment amount (and related information access, audit and other rights) in whole  or in part but not to
any direct and/or indirect competitor of the Company and/or affiliate, officer, director, employee or shareholder of such competitor.
 Any assignment by any Party of any benefit or burden under this Agreement in accordance with the provisions of this Section 6
shall not release the assigning Party from any of its obligations under this Agreement. This Agreement shall be binding on and
inure to the benefit of the Parties hereto and their respective permitted successors and assigns.

 

7.
Dispute Resolution. 

7.1
This Agreement is entered into in and shall be governed, construed and enforced in all respects solely and exclusively under the
laws of the State of New York, without giving effect to any law which would result in the application of a different body of law.
     

7.2
Any and all claims, disputes or controversies arising under, out of, or in connection with this Agreement, including any dispute
relating to patent validity or infringement, which the Parties shall be unable to resolve within sixty (60) days, shall be
mediated in good faith. The Party raising such dispute shall promptly advise the other Party of such claim, dispute or controversy
in a writing which describes in reasonable detail the nature of such dispute. By not later than five (5) business days after
the recipient has received such notice of dispute, each Party shall have selected for itself a representative who shall have the
authority to bind such Party, and shall additionally have advised the other Party in writing of the name and title of such representative.
By not later than ten (10) business days after the date of such notice of dispute, the Party against whom the dispute shall
be raised shall select a mediation firm in New York, New York and such representatives shall schedule a date with such firm for
a mediation hearing. The Parties shall enter into good faith mediation and shall share the costs equally.      

7.3
If the representatives of the Parties have not been able to resolve a dispute within fifteen (15) business days after a mediation
hearing, as set forth in Section 7.2, the Parties shall have the right to pursue any other remedies legally available to
resolve such dispute solely and exclusively in, and the parties hereby irrevocably consent to the exclusive jurisdiction and proper
venue of, the state and federal courts located in the County of New York, State of New York, USA, and waive any objections thereto
based on any ground including improper venue or Forum Non-Conveniens. The Parties agree that service of process may be effected
in accordance with Section 8.1. Any decision rendered by such court shall be binding, final and conclusive upon the Parties, and
a judgment thereon may be entered in, and enforced by, any court having jurisdiction over the Party against which an award is
entered or the location of such Party’s assets.      

    	3

    	 

    

7.4
Notwithstanding anything to the contrary herein, each Party shall be entitled to seek injunctive or other equitable relief, wherever
such Party deems appropriate in any jurisdiction, in order to preserve or enforce such Party’s rights for any breach or
threatened breach of the other Party of any of the provisions of this Agreement.

8.
Miscellaneous.

 

8.1
Notices.  Any payment, notice or other communication pursuant to this Agreement shall be sufficiently
made or given on the date of delivery if sent to such Party by recognized overnight courier or delivery service for next day delivery,
addressed to it at its address below or as it shall designate by written notice given to the other Party as follows:

 

If
to DiPerna:

Paul
M. DiPerna

17995
Bear Valley Lane

Escondido,
CA 92027

Email:
pmdiperna@gmail.com

 

If
to Company or Modular:

3
West Hill Place

Boston,
MA 02114

Attention:
Morgan Frank

Email:
mfrank@mgfund.com 

8.2
Integration.  This Agreement constitutes the entire understanding and agreement among the Parties with
respect to the transactions contemplated herein and supersede any and all prior or contemporaneous oral or written communications
with respect to the subject matter hereof, all of which are merged herein.  This Agreement shall not be modified, amended
or in any way altered except by an agreement in writing signed by authorized representatives of the Party to be bound. 

 

8.3
No Joint Venture.  Nothing contained herein will be deemed to create a joint venture or partnership or
agency relationship among the Parties.  Neither Party will have the right or authority to, and each Party will not,
assume or create any obligation or responsibility, express or implied, on behalf of or in the name of the other Party or to bind
the other Party in any manner.

 

8.4
Severability.  If any provision hereof is found invalid or unenforceable pursuant to a judicial decree
or decision, the remainder of this Agreement will remain valid and enforceable according to its terms.  Where any provision
herein has been adjudicated to exceed the maximum force allowable by law, the court will interpret such provision as providing
the maximum allowable protection provided by law.

    	4

    	 

    

8.5
Attorneys’ Fees.  The prevailing Party in any action or proceeding among the Parties arising out
of or related to this Agreement shall be entitled to recover from the other Party all of its costs and expenses including, without
limitation, its actual attorneys’ fees and costs incurred in connection with such action, including any appeal of such action.

 

8.6
Nonwaiver. The Parties agree that no failure to exercise, and no delay in exercising any right, power, or privilege
under this Agreement on the part of any Party shall operate as a waiver of any right, power, or privilege hereunder.  The
Parties further agree that no single or partial of any right, power, or privilege under this Agreement shall preclude further
exercise thereof. 

 

8.7
Authority.  Each person executing this Agreement on behalf of a Party has the authority of the entity
to execute this Agreement.

 

8.8
Time Is Of The Essence.  The Parties agree that time is of the essence with respect to each and every
term and provision set forth in this Agreement.

 

8.9
Recitals Incorporated.  The foregoing recitals are incorporated herein by reference and made a part of
this Agreement.

 

8.10
Amendments, Modifications. This Agreement may not be modified or amended in any manner except by an instrument in
writing specifically stating that it is a supplement, modification or amendment to the Agreement and signed by each of the Parties,
provided, however, that only Morgan C. Frank shall be permitted to sign for Modular, and if Mr. Frank is no longer
an officer or director of Modular, this Agreement may only be modified, amended or supplemented with the express written consent
of Manchester Management Company, LLC.

    	5

    	 

    

IN WITNESS WHEREOF, the Parties
have caused this Agreement to be executed by their duly authorized representatives as of the day and year first set forth above.

	 	 	 
	 	PAUL M. DIPERNA	 
	 	 	 
	 	

        QUASURAS, INC., a Delaware

        Corporation 
	 
	 	 	 	 
	 	By:  	 	 
	 	 	Paul
                                         M. DiPerna,

        Chief Executive Officer
	 
	 	 	 	 
	 	MODULAR
MEDICAL, INC., a Nevada Corporation
	 
	 	 	 	 
	 	By: 	 	 
	 	 	Morgan
                                         C. Frank,

        Director
	 

    	6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]